In order to successfully utilize amorphous solid dispersions (ASDs) to enhance drug
delivery, it is essential to maintain the amorphous form of the drug during the manufacturing …

When developing an amorphous solid dispersion (ASD), a prudent choice of polymer is
critical to several aspects of ASD performance including: processability, solid state stability …

PURPOSE: Development of a novel, rapid, miniaturized approach to identify amorphous
solid dispersions with maximum supersaturation and solid state stability. METHOD: Three …

Purpose To present a new screening methodology intended to be used in the early
development of spray-dried amorphous solid dispersions. Methods A model that combines …

Usage of the amorphous phase of compounds has become the method of choice to
overcome oral bioavailability problems related to poor solubility. Due to the unstable nature …

Solid state manipulation by amorphous solid dispersion has been the subject of intensive
research for decades due to their excellent potential for dissolution and bioavailability …

The biopharmaceutical properties—especially the solubility and permeability—of a molecule
contribute to its overall therapeutic efficacy. The newer tools of drug discovery have caused …

Low-solubility compounds comprise nearly one third of all active pharmaceutical ingredients
(APIs) in early development, and up to 70% of oncology and anti-infective compounds …

Purpose The use of two solvent-casted film methods to select optimal polymer compositions
for amorphous solid dispersions prepared to support preclinical pharmacokinetic and …

Spray drying is one of the most frequently used solvent-based processes for manufacturing
amorphous solid dispersions (ASDs). However, the resulting fine powders usually require …